Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas

Area of Science:

• Oncology
• Genomics
• Chemotherapy

Background:

• Temozolomide (TMZ) is a standard chemotherapy for glioblastoma (GBM).
• Understanding molecular mechanisms of TMZ sensitivity is crucial for treatment selection and prognosis in GBM patients.

Purpose of the Study:

• To identify genes and biological pathways associated with TMZ sensitivity in GBM.
• To develop a predictive gene signature for GBM patient prognosis and response to TMZ therapy.

Main Methods:

• Analysis of 34 glioma cell lines with TMZ IC50 values and RNA-seq data.
• Utilized random survival forests to identify key genes and construct a prognostic signature.
• Validated the signature using The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) datasets.

Main Results:

• Identified 1,373 genes related to TMZ response; identified epithelial-mesenchymal transition, Wnt signaling, and immune response in resistant cells.
• Discovered negative regulation of telomere maintenance via telomerase in sensitive cells, with preliminary evidence of synergistic effects with telomerase inhibitors.
• Developed a six-gene signature strongly correlating with GBM clinical characteristics and demonstrating superior prognostic accuracy compared to MGMT promoter methylation.

Conclusions:

• The developed gene signature accurately predicts glioblastoma patient survival and response to temozolomide chemotherapy.
• Identified potential therapeutic targets and provides guidance for adjuvant therapy strategies in GBM.
• A clinical nomogram integrating the signature and risk factors aids in personalized survival prediction for GBM patients undergoing TMZ treatment.